Research programme: anticancer HIF decoys - Anesiva
Alternative Names: Onco DecoyLatest Information Update: 24 Sep 2008
Price :
$50 *
At a glance
- Originator Anesiva
- Class DNA
- Mechanism of Action Transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Colorectal cancer; Lung cancer; Pancreatic cancer
Most Recent Events
- 24 Sep 2008 Discontinued - Preclinical for Colorectal cancer in USA (unspecified route)
- 24 Sep 2008 Discontinued - Preclinical for Lung cancer in USA (unspecified route)
- 24 Sep 2008 Discontinued - Preclinical for Pancreatic cancer in USA (unspecified route)